extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
 
 Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+
+Aon's 192K patient analysis found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women. This adds to the multi-organ protection thesis by quantifying sex-specific effects and demonstrating that adherence is the binding variable—benefits scale dramatically with consistent use.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -83,6 +83,12 @@ WHO's conditional recommendation requiring behavioral therapy combination provid
 
 Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+
+Aon data shows benefits scale dramatically with adherence: for diabetes indication, medical cost growth is 6 points lower at 30 months but 9 points lower with 80%+ adherence. For weight loss indication, cost growth is 3 points lower at 18 months but 7 points lower with consistent use. This confirms that low persistence rates directly undermine the economic case, as the cost savings require sustained use.
+
 ---
 
 Relevant Notes:

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so
 
 The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+
+Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects but comes from a population with better coverage than the general market. The 80%+ adherent cohort shows the strongest effects across all outcomes, suggesting that populations with coverage barriers would see substantially worse real-world outcomes, reinforcing the affordability-persistence link.
+
 ---
 
 Relevant Notes:

inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "glp-1-receptor-agonists-reduce-female-ovarian-cancer-incidence-by-50-percent-in-real-world-claims-data.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
+      "glp-1-receptor-agonists-reduce-female-ovarian-cancer-incidence-by-50-percent-in-real-world-claims-data.md:set_created:2026-03-18"
+    ],
+    "rejections": [
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
+      "glp-1-receptor-agonists-reduce-female-ovarian-cancer-incidence-by-50-percent-in-real-world-claims-data.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-18"
+}

inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md

@@ -7,9 +7,13 @@ date: 2026-01-13
 domain: health
 secondary_domains: [internet-finance]
 format: report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
+processed_by: vida
+processed_date: 2026-03-18
+enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -49,3 +53,12 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
 EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
 
 flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
+
+
+## Key Facts
+- Aon analyzed commercial health claims data from 192,000+ GLP-1 users in multi-year study released January 13, 2026
+- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users
+- After 12 months: medical costs grow 2% vs. 6% for non-users
+- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
+- Adherent users (80%+): 47% MACE reduction for women, 26% for men
+- GLP-1 users also showed lower rates of osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations